Clinical trials: Leptomeningeal Neoplasm
Brain and Central Nervous System Tumors
Topotecan in Treating Patients With Recurrent, Progressive, or Refractory Cancer That is Metastatic to the Lining Around the Brain
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of intrathecal or intraventricular topotecan in treating…
- Trial name
- NCT00025311
- Testing
- topotecan hydrochloride
- Where
- 3 sites in United States, France
- Sponsor
- NYU Langone Health
Leptomeningeal Carcinomatosis
A Safety Study of RTA 744 in Recurrent, Progressive or Refractory Neoplastic Meningitis
This study assesses the tolerability, safety, efficacy and pharmacokinetics of RTA 744 in recurrent neoplastic meningitis.
- Trial name
- LMD (NCT00527410)
- Testing
- RTA 744
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Biogen
Leptomeningeal Metastasis of HER2-positive Breast Cancer
Efficacy and Safety of Intrathecal Administration of Thiotepa in Combination With Trastuzumab in Breast Cancer With Leptomeningeal Metastasis
Evaluate the efficacy and safety of Intrathecal Administration of Thiotepa in Combination with Trastuzumab via the Ommaya Reservoir in Breast Cancer with Leptomeningeal Metastasis
- Trial name
- NCT07263425
- Testing
- Intrathecal Administration of Thiotepa in Combination with Trastuzumab via the Ommaya Reservoir
- Where
- China
- Volunteers
- 26 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Brain and Central Nervous System Tumors
Intrathecal Busulfan in Treating Patients With Recurrent, Refractory, or Metastatic Leptomeningeal Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving drugs into the thin space between the lining of the spinal cord and brain may kill more tumor cells.
- Trial name
- NCT00003462
- Testing
- busulfan
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Duke University
Cancer
Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer
Phase I trial to study the effectiveness of trastuzumab plus R115777 in treating patients who have advanced or metastatic cancer.
- Trial name
- NCT00005842
- Testing
- trastuzumab, tipifarnib
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)